Characteristics | values |
---|---|
Demographic parameters | |
Age, mean ± SD, years | 62.1 ± 17.0 |
Male/Female | 52/25 |
Comorbidities | |
Hepatic dysfunction | 2 (2.6%) |
Renal insufficiency | 7 (9.1%) |
Chronic pulmonary disease | 24 (31.2%) |
Heart disease | 14 (18.2%) |
Hypertension | 17 (22.1%) |
Diabetes mellitus | 6 (7.8%) |
Immune compromise | 5 (6.5%) |
multiple organ failure | 3 (3.9%) |
Malignancy | 8 (10.4%) |
Surgery | 16 (20.8%) |
Clinical conditions | |
CURB65 score, mean ± SD | 2.0 ± 1.0 |
Mechanical ventilation | 48 (62.3%) |
Susceptibility tests of initial airway MDRAB isolates | |
With sensitive to tigecycline | 42 (54.5%) |
With sensitive to sulbactam | 7 (9.1%) |
Tigecycline treatment | |
Duration, mean ± SD, days | 11.69 ± 6.11 |
Combination therapy | 71 (92.2%) |
With sulbactam | 64 (90.1%) |
With carbapenems | 4 (5.6%) |
With amikacin | 1 (1.4%) |
With fluoroquinolones | 4 (5.6%) |
Delayed tigecycline treatment | 21 (27.3%) |